InSilico Medicine Cayman TopCo (HKG:3696)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 22.16B |
| Revenue (ttm) | 1.06B +152.0% |
| Net Income | -2.33B |
| EPS | -7.14 |
| Shares Out | 575.84M |
| PE Ratio | n/a |
| Forward PE | 63.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,592,140 |
| Open | 41.10 |
| Previous Close | 39.44 |
| Day's Range | 38.44 - 41.32 |
| 52-Week Range | 29.98 - 80.90 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 81.40 (+111.54%) |
| Earnings Date | Aug 26, 2026 |
About HKG:3696
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, softwar... [Read more]
Financial Performance
In 2025, HKG:3696's revenue was $56.24 million, a decrease of -34.48% compared to the previous year's $85.83 million. Losses were -$352.32 million, 1960.8% more than in 2024.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for 3696 stock is "Strong Buy." The 12-month stock price target is $81.40, which is an increase of 111.54% from the latest price.
News
Insilico Medicine and Servier Achieve First Milestone in AI-Driven R&D Collaboration, Triggering An undisclosed Milestone Payment
Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. Insilico reached the first R&D milestone using its proprietary Pha...
Insilico Unveils AI-Designed ISM9546 For Inflammatory Bowel Disease And Rheumatoid Arthritis
(RTTNews) - Insilico Medicine (3696.HK), a biotechnology company that integrates AI and automation to accelerate drug discovery, has nominated a new experimental drug candidate, ISM9546, designed with...
Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
CAMBRIDGE, Mass., Sept. 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first...
Insilico's Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Too
Alex Zhavoronkov, founder and co-chief executive of techbio company Insilico, is among the scientists who have devoted countless hours to studying aging.
Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain
CAMBRIDGE, Mass., Sept. 2, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that i...
InSilico Medicine Cayman TopCo Earnings Call Transcript: Q2 2026
Revenue grew 287% year-over-year to $106.3M, with first-ever profitability and a net profit of $35.5M. Major out-licensing and AI deals drove results, while the pipeline advanced with multiple clinical milestones and novel candidates. Cash reserves remain strong at $585M.
InSilico Medicine Cayman TopCo Earnings release: Q2 2026
InSilico Medicine Cayman TopCo released its Q2 2026 earnings on August 26, 2026, summarizing the period's financial results.
InSilico Medicine Cayman TopCo Slides: Q2 2026
InSilico Medicine Cayman TopCo has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 26, 2026.
Insilico Medicine Introduces Biological Age into Virtual Cell Research: Launches Virtual Aging Cell Webpage and Previews Multi-Agent Driven VAC Generation Platform
CAMBRIDGE, Mass., Aug. 14, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), today announced ...
Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks
CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the ...
Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates
CAMBRIDGE, Mass., Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that...
Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and pre...
AI shortens drug discovery to around 1 year in China, Insilico CEO says
Hong Kong-listed Insilico Medicine has cut drug development timelines to about one year by combining AI with its China research ecosystem, its CEO said, giving it an edge over traditional Western pha...
Taiwan's Bora Pharmaceuticals in potential $2.5 billion collaboration with Insilico Medicine
Taiwan-based contract drugmaker Bora Pharmaceuticals will partner with Insilico Medicine on a collaboration aimed at improving efficiency, potentially valued at more than $2.5 billion if fully imple...
China Medical System to pay Insilico up to $177 million for nervous system work
Drugmaker China Medical System will pay Insilico Medicine up to about 1.2 billion yuan ($177 million) in milestone payments for a research and development programme in the central nervous system ...
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Hol...
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today deliv...
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader...
Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million
Takeda is set to pay InSilico to use its proprietary Pharma. AI platform to advance drug candidates across several therapeutic areas, according to people familiar with the matter.
InSilico Is on a Mission: Be No. 1 in China, Create ‘God Drug' With AI
The pharma company, the first to use generative AI to develop a drug that reached clinical trials, is betting longevity treatments will fuel its next phase of growth.